CRIS - Curis, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.5300
-0.1100 (-6.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.6400
Open1.6300
Bid1.3500 x 1400
Ask2.0000 x 1000
Day's Range1.5000 - 1.6500
52 Week Range0.6000 - 3.3300
Volume244,186
Avg. Volume606,646
Market Cap50.721M
Beta (3Y Monthly)1.44
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Curis Reports First Quarter 2019 Financial Results
    PR Newswire7 days ago

    Curis Reports First Quarter 2019 Financial Results

    LEXINGTON, Mass., May 14, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2019.

  • PR Newswire14 days ago

    Curis to Release First Quarter Financial Results and Hold Conference Call on May 14, 2019

    LEXINGTON, Mass., May 7, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter financial results on Tuesday, May 14, 2019, after the close of US markets. Management will host a conference call on the same day at 4:30 p.m. ET. To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET.

  • PR Newswire15 days ago

    Curis Completes Mesothelioma Enrollment in CA-170 Study

    LEXINGTON, Mass., May 6, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Phase 1 study of CA-170 has reached its target enrollment of mesothelioma patients. Today's announcement is a direct result of those efforts," said James Dentzer, President & CEO of Curis. CA-170 is an orally available, dual inhibitor of VISTA and PDL1, which the company believes could provide benefit in tumors with high levels of VISTA expression.

  • Curis Regains Compliance with Nasdaq Continued Listing Requirements
    PR Newswirelast month

    Curis Regains Compliance with Nasdaq Continued Listing Requirements

    LEXINGTON, Mass., April 10, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it received written confirmation from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that it has regained compliance with the minimum Market Value of Listed Securities ("MVLS") for continued listing on the Nasdaq Global Market. On December 27, 2018, the Company had received a letter from Nasdaq notifying it that it was not in compliance with the MVLS requirement set forth in Listing Rule 5450(b)(2)(A).

  • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire2 months ago

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., April 5, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 2, 2019, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 150,000 shares of Curis common stock to a new employee, with a grant date of April 2, 2019 (the "Q2 2019 Inducement Grant").

  • Curis Reports Fourth Quarter and Year-End 2018 Financial Results
    PR Newswire2 months ago

    Curis Reports Fourth Quarter and Year-End 2018 Financial Results

    LEXINGTON, Mass., March 26, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2018. "2018 was a pivotal year for Curis as we transitioned from a company broadly engaged in discovery research and pipeline expansion into a company singularly focused on clinical execution," said James Dentzer, President and Chief Executive Officer of Curis. "As we move through 2019, we are focused on the development of first-in-class and best-in-class precision medicines that we hope will transform the lives of patients," he concluded.

  • PR Newswire2 months ago

    Curis Sells Portion of Erivedge Royalties to Oberland Capital for up to $135.7 million

    LEXINGTON, Mass., March 25, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an agreement with funds managed by Oberland Capital Management, LLC ("Oberland Capital") for up to $135.7 million in exchange for selling rights to a portion of royalty revenues on worldwide net sales of Erivedge. Under the terms of the agreement, Curis received $65.0 million in an upfront cash payment, plus Curis is entitled to receive up to an additional $70.7 million in milestone payments if future net royalties exceed pre-defined annual and cumulative thresholds.

  • PR Newswire2 months ago

    Curis to Release Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 26, 2019

    LEXINGTON, Mass., March 25, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter and full-year 2018 financial results on Tuesday, March 26, 2019, after the close of the US markets. Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.

  • PR Newswire3 months ago

    Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference

    LEXINGTON, Mass. , March 4, 2019 /PRNewswire/ --   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...

  • PR Newswire3 months ago

    Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference

    LEXINGTON, Mass. , Feb. 4, 2019 /PRNewswire/ --   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...

  • PR Newswire4 months ago

    First Mesothelioma Patient Dosed in CA-170 Study

    LEXINGTON, Mass., Jan. 24, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first mesothelioma patient has been enrolled and dosed in the Phase I study of CA-170. CA-170 is an orally available, dual inhibitor of VISTA and PDL1, which the company believes could provide benefit in tumors with high levels of VISTA expression. The company had previously announced its expectation to begin enrollment of mesothelioma patients in a dedicated cohort within the existing Phase 1 study.

  • GlobeNewswire6 months ago

    Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire6 months ago

    Curis to Present at the 60th Annual Meeting of the American Society of Hematology

    LEXINGTON, Mass. , Nov. 20, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, ...

  • PR Newswire6 months ago

    Curis to Present at 33rd Society for Immunotherapy of Cancer Annual Meeting and Cowen IO NEXT Summit

    LEXINGTON, Mass. , Nov. 7, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, ...

  • PR Newswire7 months ago

    Curis Reports Third Quarter 2018 Financial Results

    LEXINGTON, Mass., Nov. 1, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2018. "Following Curis's recent leadership change, we are increasing our focus on the clinical execution of our three first-in-class therapeutics that have the potential to be significant and innovative cancer treatments. "To achieve this goal, we are re-allocating resources to prioritize clinical operations and have implemented a reduction in headcount and expenditure on pre-clinical science, pipeline expansion, and general and administrative expenses.

  • PR Newswire7 months ago

    Curis to Release Third Quarter Financial Results and Hold Conference Call on November 1, 2018

    LEXINGTON, Mass., Oct. 23, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2018 financial results on Thursday, November 1, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. ET. Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors.

  • PR Newswire8 months ago

    Curis to Present at the Cantor Fitzgerald Global Healthcare Conference

    James Dentzer, the Company's new President & Chief Executive Officer, will provide a brief overview of the Company's pipeline of drug candidates and business strategy. A live webcast of the presentation will be available by visiting the investor section of Curis' website http://investors.curis.com/events-and-presentations.

  • PR Newswire8 months ago

    Curis Announces Leadership Change

    LEXINGTON, Mass., Sept. 24, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced a change in leadership with the appointment of James E. Dentzer as President and Chief Executive Officer effective immediately. In addition, Mr. Dentzer will become a member of the Curis Board of Directors. Mr. Dentzer, who joined Curis in 2016, was promoted earlier this year to Chief Operating Officer to manage all functions outside of research and development, including business development, manufacturing, quality, human resources, finance, legal, IT, and investor and public relations.

  • PR Newswire9 months ago

    Curis to Present at the Baird 2018 Global Healthcare Conference

    LEXINGTON, Mass., Aug. 28, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will present at the Baird 2018 Global Healthcare Conference on Wednesday, September 5 at 2:35-3:05 PM in Session III - Empire Ballroom B, Mezzanine Level of the InterContinental New York Barclay in New York. The presentation will be held using a fireside-chat format in which Ali Fattaey, Ph.D. President and Chief Executive Officer, will provide a brief overview of the Company's pipeline of drug candidates and business strategy, after which an equity analyst will moderate a question and answer session. A live webcast of the presentation will be available by visiting the investors section of Curis' website http://investors.curis.com/events-and-presentations.

  • PR Newswire10 months ago

    Curis Reports Second Quarter 2018 Financial Results

    -- Management to host conference call today at 8:30 a.m. EDT -- LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization ...

  • PR Newswire10 months ago

    Curis to Release Second Quarter Financial Results and Hold Conference Call on August 2, 2018

    LEXINGTON, Mass., July 27, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2018 financial results on Thursday, August 2, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT. Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene.